LCTX

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for BioTime, Inc. (Note: The request metadata listed "Lineage Cell Therapeutics," but the filing text identifies the registrant as BioTime, Inc.) for the quarterly period ended June 30, 2002. BioTime is a development-stage biomedical company focused on research and development of synthetic plasma expanders (Hextend), blood volume substitutes, and organ preservation solutions. The company has incurred cumulative losses of $32.26 million since inception.

Key Financial Metrics

Note: Revenue consists entirely of royalties from Abbott Laboratories. No license fees were recognized in this period.

Material Changes vs. Prior Period

• Revenue Growth: Royalty revenue increased 103% year-over-year for the three months ended June 30, 2002 ($60,812 vs. $29,958), and 88% for the six-month period ($118,047 vs. $62,653). This growth is attributed to increased sales of Hextend by Abbott Laboratories.
• Expense Reduction: The company successfully reduced operating expenses. Research and Development (R&D) expenses decreased 37% for the quarter ($343,473 vs. $541,894) and 45% for the six-month period ($604,044 vs. $1,095,786). General and Administrative (G&A) expenses decreased 53% for the quarter ($290,627 vs. $613,490) and 41% for the six-month period ($622,034 vs. $1,050,487).
• Liquidity Decline: Cash and cash equivalents dropped significantly from $1,652,748 at December 31, 2001, to $501,291 at June 30, 2002, reflecting a net cash outflow of $1.15 million from operating activities.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management expects continued losses in the near future as the company funds clinical trials and regulatory applications. Future profitability depends on successful product development, regulatory approvals, and achieving revenue levels sufficient to support the cost structure.
• Debt Covenants: The company is subject to a spending restriction under its $3.35 million debenture agreement. Quarterly cash payments for operating expenses are capped at $450,000 plus cash revenues collected. This restriction expires only when the company raises $5 million in equity or pays off the debt.
• Subsequent Financing: On August 12, 2002, the company completed a private placement of 1,852,785 common shares, raising approximately $2.08 million (net proceeds ~$1.85 million) to fund clinical development and working capital.
• Risks: Key risks include the results of clinical trials, FDA regulatory approval, competition, and the ability to secure additional financing. The company has no market risk sensitive instruments.
• Unusual Items: The company recognized a benefit of $23,474 from the remeasurement of consultant stock options, recorded as an offset to R&D expenses.

Investor Verification Checklist

• Cash Runway: Verify if the $501,291 cash balance (as of June 30) combined with the subsequent $1.85 million raise is sufficient to meet the $450,000 quarterly operating cap and fund planned clinical trials.
• Debt Maturity: Confirm the status of the $3.35 million debentures due August 1, 2004, and the company's ability to refinance or repay before maturity.
• Revenue Timing: Note that royalty revenue is recognized with a lag (quarter of report receipt vs. quarter of sale). Verify if Q3 2002 will reflect the $85,843 in royalties earned in Q2 2002.
• Regulatory Status: Monitor FDA advisory committee recommendations regarding bleeding risks in cardiac surgery for hetastarch products and confirm Hextend's exclusion from these warnings.
• Share Dilution: Assess the impact of the August 2002 private placement and outstanding warrants (545,384 investor warrants and 368,201 employee options) on future earnings per share.